Clinical Trial Update: Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating IgPro20 in Post-COVID Postural Orthostatic Tachycardia Syndrome was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-covid Postural Orthostatic Tachycardia Syndrome

Drugs mentioned

• IgPro20 (intravenous immunoglobulin 20% solution)

Snippet

Sponsor: CSL Behring | Conditions: Post-COVID Postural Orthostatic Tachycardia Syndrome | Phase 3 | Status: TERMINATED | Results posted: 2026-04-13